• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Jun 8;109292.
doi: 10.1016/j.celrep.2021.109292. Online ahead of print.
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7


Bo Meng[SUP] 1 [/SUP], Steven A Kemp[SUP] 2 [/SUP], Guido Papa[SUP] 3 [/SUP], Rawlings Datir[SUP] 1 [/SUP], Isabella A T M Ferreira[SUP] 1 [/SUP], Sara Marelli[SUP] 1 [/SUP], William T Harvey[SUP] 4 [/SUP], Spyros Lytras[SUP] 5 [/SUP], Ahmed Mohamed[SUP] 6 [/SUP], Giulia Gallo[SUP] 6 [/SUP], Nazia Thakur[SUP] 6 [/SUP], Dami A Collier[SUP] 2 [/SUP], Petra Mlcochova[SUP] 1 [/SUP], COVID-19 Genomics UK (COG-UK) Consortium; Lidia M Duncan[SUP] 1 [/SUP], Alessandro M Carabelli[SUP] 7 [/SUP], Julia C Kenyon[SUP] 8 [/SUP], Andrew M Lever[SUP] 9 [/SUP], Anna De Marco[SUP] 10 [/SUP], Christian Saliba[SUP] 10 [/SUP], Katja Culap[SUP] 10 [/SUP], Elisabetta Cameroni[SUP] 10 [/SUP], Nicholas J Matheson[SUP] 11 [/SUP], Luca Piccoli[SUP] 10 [/SUP], Davide Corti[SUP] 10 [/SUP], Leo C James[SUP] 3 [/SUP], David L Robertson[SUP] 5 [/SUP], Dalan Bailey[SUP] 12 [/SUP], Ravindra K Gupta[SUP] 13 [/SUP]



Collaborators, Affiliations

Abstract

We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K and Y453F, known to increase binding affinity to the ACE2 receptor and confer antibody escape. In vitro, we show that, although ΔH69/V70 itself is not an antibody evasion mechanism, it increases infectivity associated with enhanced incorporation of cleaved spike into virions. ΔH69/V70 is able to partially rescue infectivity of spike proteins that have acquired N439K and Y453F escape mutations by increased spike incorporation. In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where ΔH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped virus. Alpha variant B.1.1.7 spike mediates faster kinetics of cell-cell fusion than wild-type Wuhan-1 D614G, dependent on ΔH69/V70. Therefore, as ΔH69/V70 compensates for immune escape mutations that impair infectivity, continued surveillance for deletions with functional effects is warranted.

Keywords: Alpha variant; B.1.1.7; COVID-19; SARS-CoV-2; antibody escape; deletion; infectivity; neutralizing antibodies; resistance; spike mutation.
 
Back
Top Bottom